{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:06:16Z","timestamp":1791353176505,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd003805","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T00:00:00Z","timestamp":1192579200000}}],"reference-count":67,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003805.pub2","type":"journal-article","created":{"date-parts":[[2007,10,10]],"date-time":"2007-10-10T12:19:30Z","timestamp":1192018770000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma"],"prefix":"10.1002","volume":"2010","author":[{"given":"Holger","family":"Schulz","sequence":"first","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bohlius","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Trelle","sequence":"additional","affiliation":[{"name":"University of Bern; Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine; Finkenhubelweg 11 Bern Switzerland CH-3012"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Kober","sequence":"additional","affiliation":[{"name":"Smiling Press Productions; 3 Ulm Street Scullin Australia ACT 2614"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen-Gro\u00dfhadern; Medizinische Klinik III; M\u00fcnchen Germany 81366"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Herold","sequence":"additional","affiliation":[{"name":"2. Medizinische Klinik, Helios Klinikum Erfurt; Medical Clinic Hematology\/Oncology; Nordh\u00e4user Stra\u00dfe 74 Erfurt Germany 99089"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Schwarzer","sequence":"additional","affiliation":[{"name":"German Cochrane Center; Department of Medical Biometry and Statistics; University Medical Center Stefan-Meier-Str. 26 Freiburg Germany D-79104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,17]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD003805.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Herold M Pasold R Srock S Neser S Niederwieser D Neubauer A Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin's Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL) ASH Annual Meeting Abstracts 2004 584","DOI":"10.1182\/blood.V104.11.584.584"},{"issue":"12","key":"10.1002\/14651858.CD003805.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD003805.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1002\/14651858.CD003805.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Rivas-Vera S Baez E Sobrevilla-Calvo P Baltazar S Tripp F Vela J Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin's Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP ASH Annual Meeting Abstracts 2005 2431","DOI":"10.1182\/blood.V106.11.2431.2431"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.","volume":"108 (10)","author":"Oers","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0009|cit9","first-page":"abstract 1393","article-title":"Results of a phase II study employing a combination of Fludarabine, Cyclophosphamide and Rituximab (FCR) as a primary therapy for patiens with advanced follicular lymphoma (FL): the israel cooperative group","volume":"100, No 11","author":"Cohen","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0010|cit10","first-page":"694","article-title":"Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.","volume":"Feb 1; 23 (4)","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol. 2005 Feb 1;23(4):694-704"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.","volume":"Dec 1; 22 (23)","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0012|cit12","first-page":"278","article-title":"Rapid clearance of circulating lymphoma cells from peripheral blood of follicular lymphoma patients treated with chemotherapy and rituximab as compared to patients treated with chemotherapy alone","volume":"3 Suppl. 1","author":"Doelken","year":"2002","journal-title":"Hematology"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.","volume":"103 (12)","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0014|cit14","first-page":"abstract 1499","article-title":"A phase II study of ludarabine and mitoxantrone followed by anti-CD 20 monoclonal antibody in the treatment of patients with newly diagnosed, advanced low grade non Hodgkin\u00b4s lymphoma (LGNHL): interim results","volume":"102, 11, Part 1","author":"Gregory","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.","volume":"23 (6)","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"H. S. Hochster E. Weller T. Ryan T. M. Habermann R. Gascoyne S. R. Frankel S. J. Horning Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) ASCO Annual Meeting Proceedings (Post-Meeting Edition). abstract 6502 Vol 22, No 14S (July 15 Supplement), 2004: 6502 2004","DOI":"10.1200\/jco.2004.22.90140.6502"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Jane E. Huang Lowell Hart Jonathon Polikoff Virginia Langmuir Fan Zhang Louis Fehrenbacher Rituximab Plus CHOP Followed by Maintenance Rituximab as Initial Therapy for Advanced Stage Indolent Non-Hodgkin\u2019s Lymphoma (NHL); Initial Results of Induction Therapy in a Phase II Study. Blood (ASH Annual Meeting Abstracts), abstract: 4615. 2004","DOI":"10.1182\/blood.V104.11.4615.4615"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0018|cit18","unstructured":"Yunfang Jiang Peter McLaughlin Athanasios Thomaides David Simons Ajay Sehgal Thomas Sneed Ofelia Mesina Marilyn Clemons Ana Ayals Georgios Z. Rassidakis L. Jeffrey Mederios Andreas H. Sarris Frederic Gilles Fernando Cabanillas Andre Goy Quantification and Monitoring of the t(14;18) Translocation Copy Number by Real-Time PCR in Patients with Follicular Lymphoma Treated with FND Plus Concurrent or Delayed Rituximab Amercian Society of Hematology : abstract 1444 2003"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Suresh B. Katakkar A Combination of Rituximab with Chemotherapy in Low Grade Lymphoma Blood (ASH Annual Meeting Abstracts) abstract 4647 2004","DOI":"10.1182\/blood.V104.11.4647.4647"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0020|cit20","unstructured":"G. Meckenstock S. Martin G. Kobbe P. M\u00f6ller M. Bentz C. Aul A. Raghavachar A. Wehmeier D. Braumann C. Losem A. Nusch R. Kronenwett H. D\u00f6hner R. Haas Firstline treatment of advanced follicular lymphoma comparing fludarabine\/Mitoxantrone and high-dose chemotherapy, each combined with CD20-antibody rituximab Onkologie; abstract 869 2003"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0021|cit21","unstructured":"Pettengell R Linch DC Phase III Randomized Study of Rituximab Purging and Maintenance With Perupheral Blood Stem Cell Transplantation in Patients With Relapsed or Resistant Follicular Non-Hodgkin's Lymphoma Undergoing High-Dose Chemotherapy Ongoing Clinical Trial"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0022|cit22","first-page":"abstract 1487","article-title":"Long term improvement of clinical outcomes of follicular lymphoma patients achieving a molecular response after sequential CHOP and rituximab treatment: predictive value of real time quantitative PCR to identify responding patients","volume":"102, No 11, Par","author":"Rambaldi","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0023|cit23","unstructured":"Rule S Seymour J Phase II Randomized Study of Fludarabine and Cyclophopshamide With or Without Rituximab inPatients With Previously Untreated Mantle Cell Lymphoma Ongoing Trial"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Gilles Andre Salles Charles Foussard Mounier Nicolas Morschhauser Franck Doyen Chantal Lamy Thierry Haioun Corinne Brice Pauline Bouabdallah Reda Rossi Jean-Fran\u00e7ois Audhuy Bruno Ferm\u00e9 Christophe Mahe B\u00e9atrice Feugier Pierre Sebban Catherine Colombat Philippe Xerri Luc Rituximab Added {alpha}IFN+CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: to First Analysis of the GELA-GOELAMS FL-2000 Randomized Trial in 359 Patients. ASH Annual Meeting Abstracts 2004 160","DOI":"10.1182\/blood.V104.11.160.160"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Philippe Solal-Celigny Gilles Andre Salles Nicole Brousse Patricia Franchi-Rezgui Pierre Soubeyran Vincent Delwail Eric Deconinck Corinne Haioun Charles Foussard Catherine Sebban Herve Tilly Noel-Jean Milpied Francois Boue Jean-Michel Karsenti Pierre Lederlin Albert Najman Catherine Thieblemont Franck Morschhauser Nathalie Berriot-Varoqueaux Loic Bergougnoux Philippe Colombat Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F\/Up) of at Least 5 Years. ASH Annual Meeting Abstracts 585 2004","DOI":"10.1182\/blood.V104.11.585.585"},{"issue":"4","key":"10.1002\/14651858.CD003805.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1349-7006.2006.00173.x","article-title":"Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma","volume":"97","author":"Ogura","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1002\/14651858.CD003805.pub2-BIB0027|cit27","first-page":"abstract 1452","article-title":"A brief course of chemo-immunotherapy FND + rituximab is effective to induce a high clinical and molecular response in elderly patients with advanced stage follicular lymphoma (FL) at diagnosis\"","volume":"102, 11, Part1,","author":"Vitolo","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003805.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","article-title":"Fludarabine plus mitoxantrone with and without rituximab vs as front-line treatment for patients with follicular lymphoma","volume":"22","author":"Zinzani","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0030|cit30","unstructured":"Groupe d\u2019Etudes de Lymphomes de L\u2019Adulte HOVON\u2014Dutch Haemato-Oncology Association German Low Grade Lymphoma Study Group OSHO Australasian Leukaemia and Lymphoma Group (ALLG) Institute of Cancer Research United Kingdom. Advanced Advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab (MabThera) after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy. Ongoing clinical trial Available at: clinicaltrials.gov NCT00140582"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0031|cit31","unstructured":"Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Ongoing study January 2002"},{"issue":"7223","key":"10.1002\/14651858.CD003805.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"issue":"9383","key":"10.1002\/14651858.CD003805.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD003805.pub2-BIB0034|cit34","first-page":"96","article-title":"Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"91","author":"Barosi","year":"2006","journal-title":"Haematologica"},{"issue":"1-2","key":"10.1002\/14651858.CD003805.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.drup.2005.02.004","article-title":"Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma","volume":"8","author":"Bonavida","year":"2005","journal-title":"Drug Resist Updat"},{"issue":"4","key":"10.1002\/14651858.CD003805.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003805.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.critrevonc.2005.10.001","article-title":"Treatment of mantle cell lymphoma: current approach and future directions.","volume":"58","author":"Brody","year":"2006","journal-title":"Critical Reviews in Oncology Hematology"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.","volume":"17","author":"Czuczman","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1002\/14651858.CD003805.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003805.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biotherapy & Radiopharmaceuticals"},{"issue":"6964","key":"10.1002\/14651858.CD003805.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/jco.2006.24.18_suppl.7502","article-title":"Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).","volume":"24 (Suppl)","author":"Dreyling","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"7109","key":"10.1002\/14651858.CD003805.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"18","key":"10.1002\/14651858.CD003805.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD003805.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD003805.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD003805.pub2-BIB0048|cit48","first-page":"suppl","article-title":"Diffuse large B-cell lymphoma","volume":"3","author":"Habermann","year":"2005","journal-title":"Clinal Advances in Hematology Oncology: H&O"},{"issue":"5 Suppl 5","key":"10.1002\/14651858.CD003805.pub2-BIB0049|cit49","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Seminars Oncology"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","article-title":"a language for data analysis and graphics","volume":"5","author":"Ihaka","year":"1996","journal-title":"J Computat Graph Stat"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0051|cit51","first-page":"6","article-title":"Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Systematic Review. Evidence-based Series 6-8","volume":"2","author":"Imrie","year":"2005","journal-title":"Cancer Care Ontario, Program in Evidence-Based Care (PEBC)"},{"issue":"13","key":"10.1002\/14651858.CD003805.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"10.1002\/14651858.CD003805.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","article-title":"Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis","volume":"65","author":"Jazirehi","year":"2005","journal-title":"Cancer Reserach"},{"issue":"7303","key":"10.1002\/14651858.CD003805.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"Juni","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0055|cit55","first-page":"No.: CD003805.","article-title":"Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. (Protocol)","volume":"4","author":"Kober","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0056|cit56","first-page":"6","article-title":"Cancer statistics, 1998 Cancer statistics, 1998 Cancer statistics, 1998","volume":"48","author":"Landis","year":"1998","journal-title":"CA: A Cancer Journal for Clinicans"},{"issue":"10","key":"10.1002\/14651858.CD003805.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/1097-0142(19861015)58:8<1596::AID-CNCR2820580803>3.0.CO;2-G","article-title":"Stage I-II follicular lymphoma treatment results for 76 patients","volume":"58","author":"McLaughlin","year":"1986","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD003805.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003805.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/1042819021000050052","article-title":"Incidence and clinical significance of bcl-2\/IgH rearrangements in follicular lymphoma","volume":"44","author":"Montoto","year":"2003","journal-title":"Leul Lymphoma"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0062|cit62","first-page":"1862","article-title":"Report of the committee on Hodgkin\u2019s disease staging procedures.","volume":"31","author":"Rosenberg","year":"1971","journal-title":"Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD003805.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD003805.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem cell support for chemosensitive transformed low-grade follicular non-Hodgkin\u2019s lymphoma: a case-matched study for the European Bone Marrow Transplant Registry.","volume":"19","author":"Williams","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0066|cit66","first-page":"502","article-title":"To what extent can indolent lymphoma be considered? Results of a long term follow-up study from a single center.","volume":"83","author":"Zinzani","year":"1998","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD003805.pub2-BIB0067|cit67","first-page":"706","article-title":"Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"Journalof National Cnacer Institute"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003805.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:18:03Z","timestamp":1760613483000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003805.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2007,10,17]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003805.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,17]]}}}